A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Grants and Contracts Details

StatusFinished
Effective start/end date4/22/109/30/11

Funding

  • Cytokinetics Incorporated: $17,341.00